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____________________________________________________________________ 8 
This study used a geographic based water model to predict the environmental concentrations of 9 
three pharmaceuticals 17-ethinylestradiol (EE2), 17-estradiol (E2) and diclofenac throughout  10 
European rivers.  The work was prompted by the proposal of the European Community 11 
(COM(2011)876) to consider these chemicals as candidates for future control via environmental 12 
quality standards (EQS).  National drug consumption information, excretion, national water use, and 13 
sewage removal rates, were used to derive per capita sewage effluent values for the European 14 
countries .   For E2, excretion rates of the natural hormone and national demographics were also 15 
included.    Incorporating this information into the GWAVA model allowed water concentrations 16 
throughout Europe’s rivers to be predicted.  The mean concentration from the expected sewage 17 
discharge scenario indicated that 12% by length of Europe’s rivers would reach concentrations 18 
greater than the proposed 0.035 ng/L EQS for EE2.  For several countries, between a quarter and a 19 
third of their total river length would fail such an EE2 EQS.  For E2, just over 1% by length of rivers 20 
would reach concentrations greater than the 0.4 ng/L proposed EQS, whilst just over 2% by length of  21 
rivers would reach concentrations greater than the proposed EQS of 100 ng/L for diclofenac.   22 
Key words 23 
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Introduction 26 
 The control of what are called hazardous substances in Europe falls under the Water Framework 27 
Directive (WFD).  When an environmental quality standard (EQS) is set for a chemical this can lead to 28 
it being phased out of production.   However, the very recent addition of the pharmaceuticals 17a-29 
ethinylestradiol (EE2), 17b-estradiol (E2) and diclofenac in the European Community document 30 
(COM(2011)876) appear to usher in a new era.  This document suggested annual average EQS of 31 
0.035 ng/L for EE2, 0.4 ng/L for E2 and 100 ng/L for diclofenac.  Now this document has been 32 
amended and these drugs put on a watch list until they are reviewed again in 2014.  Thus, there 33 
remains the possibility that they will become controlled with an EQS in due course. 34 
Given their societal health benefits, it is unlikely and perhaps undesirable for particular 35 
pharmaceuticals to be phased out on the basis of environmental concerns.  Thus, as source controls 36 
are inappropriate, so end of pipe solutions may have to be sought.  A number of studies have 37 
examined the efficacy of different sewage tertiary treatments and indeed one European State, 38 
Switzerland, is planning to invest in such technology [1].  Based on our current knowledge, most of 39 
the proposed techniques would appear to be very expensive to build and maintain [2, 3].  As an EQS 40 
would be set for the receiving waters and not the sewage effluent, so the extent of investment will 41 
depend on the available dilution.  Thus, the magnitude of the challenge for different nations will 42 
reflect their unique geographical and hydrological circumstances.  Examining the extent of these 43 
differences in national exposure would appear to be vital information in engaging not only 44 
regulators, water utilities, government and environmental scientists, but also the general public too.   45 
Geographic-based water quality models are a practical tool that can address the question of 46 
exposure to pharmaceuticals at a continental scale.  Measuring all of these chemicals throughout 47 
every European river would be exceedingly costly and time consuming, to say nothing of the 48 
problems of consistency.  Measuring EE2 throughout Europe’s rivers would be impractical, since very 49 
few, if any, chemists can confidently claim to quantify EE2 at concentrations of 0.035 ng/L with 50 
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current technology.   The strengths and weaknesses of water quality modelling vs measuring have 51 
been reviewed before, but it is important to note that models have no lower detection limit [4]!   52 
Before considering how to approach this task, it is worth briefly reviewing what evidence 53 
brought these chemicals to the attention of the EU.  Following a series of surprising observations on 54 
the effects of fish being exposed to sewage effluent in the mid 1980s’ in the UK, a series of 55 
methodical studies were carried out which revealed that something in effluent could provoke 56 
endocrine disruption [5].  Field surveys then revealed that endocrine disruption of fish was 57 
widespread in wild fish caught in proximity to sewage treatment plants [6] and that the most potent 58 
component of that effluent was the fraction containing steroid estrogens [7].  Amongst those steroid 59 
estrogens, E2 and the synthetic estrogen EE2 were demonstrated to be the most potent [8].  These 60 
observations were repeated by scientists throughout the world.  Whilst the disrupting effects of E2 61 
and EE2 at low ng/L exposure concentrations on individual fish are undeniable, the assessment of 62 
the effect of that disruption on fish populations is less secure [9].  Diclofenac came to prominence 63 
when it was strongly implicated in the poisoning and decline of vulture populations in Asia [10].  A 64 
number of studies have suggested that low µg/L concentrations of diclofenac adversely affect fish 65 
[11, 12], and raised concern that diclofenac might pose a threat to wild fish.  However, a recent 66 
study failed to support the results of these earlier studies, and instead found that adverse effects on 67 
fish occurred only when the environmental concentration approached 1mg/L [13], which is very 68 
much higher than any river concentration is likely to be. 69 
If these pharmaceuticals stay on the watch list and even become priority substances needing 70 
control, so it is likely other pharmaceuticals will follow.  A stated objective of the European 71 
Parliament legislative resolution of 2 July 2013 amending Directives 2000/60/EC and 2008/105/EC as 72 
regarding putting chemicals on a watch list (COM(2011)0876 – C7-0026/2012 – 2011/0429(COD)) is 73 
that this will stimulate further studies both in terms of monitoring and on the risks they pose.  To 74 
respond the objectives of this study were: 75 
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 To refine and adapt existing models for E2, EE2 and diclofenac using the most recent 76 
consumption information to predict European river water concentrations 77 
 To examine how close predicted river concentrations would exceed proposed EQS levels of 78 
0.4 ng/L for E2, 0.035 ng/L EE2 and 100 ng/L diclofenac across Europe 79 
 To identify the European countries most likely to be challenged if such EQS levels had to be 80 
achieved. 81 
Materials and methods 82 
Assessing per capita consumption rates.  The approach to estimating sewage effluent 83 
concentrations takes the drug consumption per capita for a specific nation, less that prevented from 84 
being excreted as the free parent compound, and less that removed in sewage treatment.  The 85 
effluent concentration is then calculated by dividing this figure by the per capita wastewater 86 
discharge for that nation: 87 
 88 
W 
       
 
 89 
 90 
Where C is consumption of the drug as ng/cap/d; E is the amount of the drug that is not excreted 91 
(ng/cap/d); S is the amount of the drug that is prevented from escaping into sewage effluent 92 
(ng/cap/d); D is the diluting volume of wastewater as L/cap/d; and W is the effluent concentration as 93 
ng/L. 94 
The river concentration at the point of the effluent discharge (Rm, ng/L) is calculated by mass 95 
balance, and loss of the compound due to aquatic processes such as sedimentation and 96 
transformation is accounted for with a first order dissipation process to give the downstream 97 
concentration (Rd, ng/L). 98 
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Where, k is the decay rate (days-1) and t is the time of travel (days). The time of travel is the river 100 
reach volume divided by the flow rate [14]. 101 
The most critical part of any predictive model used to assess concentrations of human 102 
derived chemicals in water is obtaining information on usage.   National databases and academic 103 
studies can be interrogated to assess a per capita consumption value, given the human population of 104 
the country at that time (Table 1). 105 
TABLE 1. Range of national pharmaceutical per capita consumption values and their year of origin 106 
Country EE2 
consumption 
(g/cap/d) 
Ref source E2 (HRT) 
consumption 
(g/cap/d)* 
Ref Source Diclofenac 
consumption 
(g/cap/d) 
Ref Source 
Belgium 2.11 (2007) [15] NA NA NA NA 
France 1.54 (2007) [15] NA NA 449 (2004) [16] 
Germany 1.69 (2007) [15] NA NA 2613 (2003) [17] 
Italy 0.94 (2007) [15] NA NA NA NA 
Netherlands 2.59 (2012) [18] 1.7 (2011) GIPdatabank 
(www.gipdatab
ank.nl) 
1205 (2012) [18] 
UK  1.21 (2007) [15] 5.7 (2010) NHS dataset 
(www.ic.nhs.uk
) 
957 (2010) NHS dataset 
(www.ic.nhs.uk) 
Spain  1.0 (2003) [19] NA NA 2124 (2003) [19] 
Sweden  0.84 (2010) Apotekensservice 
(www.apotekenss
ervice.se) 
15.7 (2010) Apotekensservi
ce 
(www.apoteke
nsservice.se) 
1351 (2010) Apotekensservice 
(www.apotekensservic
e.se) 
Poland  1.0 (2000) [20] NA NA 1482 (2000) [20] 
Switzerland  2.0 (2000) [19] NA NA 1459 (2000) [19] 
Denmark  NA† NA NA NA 520 (2009) Danish medicine 
statistics (www.ssi.dk) 
Czech 
Republic 
1.18 (2012) SUKL database 
(www.sukl.cz) 
4.1 (2012) SUKL database 
(www.sukl.cz) 
1075 (2012) SUKL database 
(www.sukl.cz) 
Norway 1.51 (2011) Norwegian 
Prescription 
Database 
(www.norpd.no) 
7.9 (2011) Norwegian 
Prescription 
Database 
(www.norpd.n
o) 
1059 (2011) Norwegian 
Prescription Database 
(www.norpd.no) 
Mean 1.47  7.0  1299  
†NA = Not Available   *HRT = Hormone Replacement Therapy 107 
Ethinylestradiol consumption, excretion, and environmental fate.  Recent values for EE2 108 
consumption in different European countries that are available show only a small variation in 109 
individual EE2 consumption values (Table 1 & 2).  The probable excretion rate of EE2 by humans has 110 
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been extensively reviewed  [21] and this also shows only modest variation (Table 2).  Information on 111 
removal in sewage treatment is available [21-27] and a wide variation in performance is apparent 112 
(Table 2).     EE2 is still considered the most persistent of the steroid estrogens ,with a modest half 113 
life in water of 17 d and also a slow photodegradation rate [28, 29]. The model used here for 114 
predicting EE2 concentrations in sewage effluent and receiving waters [21] has been compared 115 
previously against measured concentrations [30-32].  An agreement value can be given by dividing 116 
the observed by the modelled concentration, such that one is a perfect match, less than one an 117 
overestimate and greater than one an underestimate.  For EE2 the result is 0.2-2.0 (n=20) for these 118 
studies which is within an order of magnitude difference [30, 31]. 119 
Estradiol consumption, excretion, and environmental fate.  Estradiol is one of the natural estrogen 120 
hormones circulating in the human body and is indeed common to all vertebrates [33].  It is also 121 
provided as an active ingredient of many hormone replacement therapies (HRT) and as an ester pro 122 
drug (estradiol valerate) in some new contraceptive formulations.  The most important contributors 123 
of natural E2 are pregnant women, providing an estimated 63% of the natural E2 load in the UK [21], 124 
followed by menstrual women (18%).   For this study the demographics of each European nation was 125 
assessed and the number of males, menstrual, menopausal and pregnant females recorded [34].  To 126 
calculate a per capita E2 discharge for each nation, the assumed E2 excretion rate (g/cap/d) for 127 
each population sub-group [21] was multiplied by the number of people in each category.  It should 128 
be noted that obtaining a value for the number of pregnant women is particularly complex as 129 
abortions, foetal deaths, live births and multiple births for each country have to be disentangled 130 
from a range of sources.  This value was normalised by dividing by the total population to give a per 131 
capita natural E2 value.  To this natinal natural E2 value was added the per capita HRT E2 value 132 
where known, or otherwise a European average value, to calculate a national total E2 discharge 133 
value (Table 2).  Recently, the topic of human E2 excretion was reviewed [35] for the US and a value 134 
of 7.87 g/cap/d was reported, which is very similar to that previously calculated for E2 [21] in the 135 
UK and the range calculated for this study (4-8 g/cap/d) .   136 
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 Given the amount of E2 excreted by women on HRT and the proportion present as the 137 
parent or glucuronide then only 3-10% of the pharmaceutical E2 ingested would be excreted [21, 36, 138 
37].  This implies that for the countries for which we have data (Table 1), only 1-8% of the total E2 139 
arriving at a sewage treatment plant (STP) would have originated from pharmaceutical sources.      140 
It was assumed that 50% of E2 will convert to E1 in the sewers before arriving at a STP 141 
following the suggestion of earlier models [21] (Table 2).  Information on removal in sewage 142 
treatment is fairly consistent [22-25, 27, 38-40], with a mean removal of 89% being recorded (Table 143 
2).  No type of biological sewage treatment (such as between trickling filter and activated sludge) is 144 
significantly worse than any other in removing E2 [41]. The ready degradability of E2 in river water 145 
samples indicates half-lives of 0.2 to 8.7 d could be expected [28], and the dissipation observed in 146 
the field appears to correspond to such rates [42].  This approach to predicting E2 concentrations in 147 
sewage effluent and receiving waters has been compared previously against measured 148 
concentrations and found to give an observed over modelled agreement ratio of 1.3 (n=3) at one 149 
plant effluent [30] and 0.4 (n=19) for 19 STP effluents with an agreement ratio of 0.5-0.7 for a 34 km 150 
river stretch [31].   151 
There is a danger that modelling river E2 concentrations on the basis of human inputs alone 152 
may underestimate the situation in areas where livestock predominate.  Whilst some evidence for a 153 
link between the presence of livestock and river estrogens have been made [43] widespread 154 
endocrine disruption remains most closely associated with STPs [32] and E2 river predictions at least 155 
in the UK can be explained by sewage inputs [31, 44]. 156 
Diclofenac consumption, excretion, and environmental fate.  Diclofenac (2-[2,6-157 
dichlorophenyl)amino]benzeneacetic acid is a popular non-steroidal anti-inflammatory drug often 158 
used to treat rheumatic type pain.  The variation in national diclofenac consumption rates appears 159 
to be wider than for the other two drugs (Table 1 and 2).  The range in diclofenac excretion values 160 
has been reviewed previously [45] and appears to be more variable than the range for EE2.  Whilst 161 
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there again appears to be quite large variability [18, 46-56], the weighted mean sewage removal of 162 
diclofenac is poor at only 22% (Table 2).  Photodegradation has been put forward as an important 163 
removal mechanism in surface waters  [57-59].  In reality, leaving darkness aside, conditions in the 164 
field are often not ideal for photodegradation, so removal along a river, where residence times are 165 
typically much shorter than lakes, can be negligible for diclofenac [57, 60].  Given this uncertainty it 166 
was considered prudent to exclude attenuation in predictions for this molecule in river water.  The 167 
modelling approach for predicting diclofenac concentrations was similar to that carried out  168 
previously [45], but now with slightly changed parameters (consumption, excretion and sewage 169 
removal) informed by more recent literature.  As this diclofenac method has not been tested 170 
previously, this was examined using relatively recent sewage effluent measured values from 171 
composite samples where inhabitant and flow information permitted predictions to be made [18, 172 
54, 61, 62](Table S1).   173 
TABLE 2. Range of factors affecting the model and their potential impact on the outcome.  Note 174 
where sufficient data permits a weighted mean is given followed by the best and worst case value 175 
given in parenthesis. 176 
Factor EE2 E2 Diclofenac 
Consumption range across 
nations (g/cap/d) 
0.84-2.59 4.1-8.2
a
 449-2613 
Apparent consumption 
variation 
3-fold 2-fold 6-fold 
Weighted mean with lowest 
and highest patient 
excretion values (%) 
40 (21-54) NA 9.5 (2-23) 
Potential effect on influent 
concentration 
3-fold NA 11-fold 
Weighted mean with lowest 
and highest sewage 
treatment removal (%) 
68 (0-90) 89 (69-99) 22 (0-82) 
Potential effect on sewage 
effluent concentration 
10-fold 31-fold 5-fold 
Potential effect on drug 
concentations by combining 
effects of excretion and 
sewage treatment removal  
factors. 
26-fold 31-fold 64-fold 
In stream half-life in days 
(20
o
C) 
17.3 2.3 (0.3-8.7) Not used 
Range of dilution factors 
across Europe (m
3
/cap/d) ** 
2.8 - 2.7∙10
3
 
Potential effect on water 
concentration 
1000-fold 
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a
 As E2 is largely an endogenous hormone we cannot discuss it in terms of consumption and excretion rate.  177 
The values given are the concentration excreted by a ‘normalised human’ [21] modified by national 178 
demographics and HRT use differences where known 179 
**10%ile to the 90%ile of dilution values calculated on a cell-by-cell basis using 1970-2000 average river 180 
discharge 181 
 182 
European river water modelling.  To examine potential concentrations of these chemicals 183 
throughout European surface waters, the geographic-based water resources model GWAVA run in a 184 
water quality mode was used [14]. This model uses geographic data on the location and size of the 185 
human European population and their association with STPs.  The version of GWAVA used here 186 
incorporates a newly available and extensive dataset (2009-2010 information) of locations and 187 
number of people connected to sewage discharge points in Europe [63].   The flows through these 188 
STPs are incorporated with the natural river discharge adjusted for abstractions (principally for 189 
potable supply and agriculture).  The hydrology is driven by monthly climate over the period 1970-190 
2000.    The ability of GWAVA to simulate river flows has been previously tested against gauged 191 
flows across Europe, and other continents. Also modelled water quality determinands have been 192 
compared with measured data [14].   The chemical inputs of per capita drug consumption, excretion, 193 
removal in sewage, and in-stream half- life were provided by this study (Table 2).  The model 194 
calculates the water concentrations of chemicals through water courses in a series of 177,470 grid 195 
squares (cells) of approximately 6 x 9 km (5 by 5 Arc minutes) dimensions. On a monthly basis, in the 196 
water courses in each cell receiving effluent, the concentration is calculated by diluting the mass of 197 
chemical discharged in the volume of water in the cell accounting for any loads from upstream cells. 198 
The chemicals are transported downstream with the discharge to the next cell. Chemical can be lost 199 
through abstraction or a first-order dissipation process.  The time of travel though the gridded 200 
network (which can comprise rivers, lakes and wetlands) is calculated from the river flow rate and 201 
the water volume of each cell. Surface water volumes are estimated using established empirical 202 
relationships with width and depth data [14]. Thus, the model was set up using either the national, 203 
or mean, per capita consumption for EE2 and diclofenac for each country as appropriate (Table 1).  204 
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For E2, a value for each nation was derived from its population demographics plus pharmaceutical 205 
E2 use where known (Table 1).  The mean value for each grid square was then used as the output.  206 
This was considered the most relevant output given that the proposed EQS in the EU 207 
(COM(2011)876) document would use an annual average (AA) value.  The model output and its 208 
statistical analysis can be for a continent, for separate nations or even for individual river basins 209 
based on selecting the appropriate cells.  Trans-boundary flows and their pollutant load are always 210 
accounted for. 211 
Scenario analysis.  There are uncertainties in the model parameters determining effluent 212 
concentrations, which are critical in estimating river concentrations.  In order to assess the impact of 213 
this uncertainty, a series of scenarios were run to establish the range of likely river concentrations 214 
(and hence likely EQS  exceedence) , based on the reported literature values. These scenarios were a 215 
best case - low excretion, high sewage removal and high in stream dissipation; a worst case - high 216 
excretion, low removal and slow in stream dissipation and an expected case, which used weighted 217 
average values for these parameters (Table S2). The envelope of possible effluent concentrations 218 
from the best and worse case scenarios was large differing by factors of approximately 26 for EE2, 31 219 
for E1 and 64 for diclofenac  (Table 2). The expected scenario based on the mean literature values   220 
gives reasonable agreement with the few available measured data (see above and results section), 221 
with the other cases giving the extreme values.  222 
   223 
Results and Discussion 224 
Ability to predict diclofenac concentrations in effluent.  The predicted and measured effluent 225 
diclofenac concentrations were compared by dividing the measured by the predicted value to give 226 
an agreement ratio (Table S1).   Based on this small comparison, with agreement ratios between 0.5 227 
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and 8.7, it appears the diclofenac predictions were broadly acceptable (Table S1) but with a 228 
tendency to underestimate. 229 
 Predicted exceedences of proposed European EQS values.   Before starting the 230 
water quality modelling, based on the European mean consumption values, excretion values and 231 
sewage removal factors (Tables 1 and 2) then 1 ng/L EE2, 3 ng/L E2 and 570 ng/L diclofenac  would 232 
be expected in European sewage effluents.  It should be noted that where data were lacking, such as 233 
in some Eastern European countries, European average drug consumption values were used.    Apart 234 
from predicting the consumption value correctly, it can be seen that variations in the hydrological 235 
dilution component will have the biggest impact on the outcome (Table 2).  Rivers where an annual 236 
average concentration of EE2 would exceed 0.035 ng/L would be fairly widespread with the 237 
expected scenario (Fig. 1).  Of perhaps greater biological significance is where EE2 concentrations 238 
might exceed 0.35 ng/L [8, 64]and this is far less widespread but not negligible (Fig. 1).  When all the 239 
results are plotted as cumulative frequency distributions, both as the expected (Fig. 2) together with 240 
the best and worst case (Fig. S1 and S2) scenarios and compared with the proposed EQS values it can 241 
be seen that EE2 would pose the greatest challenge.  It can be observed that 74% of Europe’s rivers 242 
by length receive some sewage input whilst the remaining lengths have negligible human input (Fig. 243 
2).  Between 2 and 25% by length of Europe’s rivers were predicted to have EE2 concentrations in 244 
excess of 0.035 ng/L (best and worst case) with the expected outcome being 12% (Fig. 2).  For E2 245 
between 0-6% of river lengths were predicted to exceed 0.4 ng/L (1.5% expected exceedance) and 246 
for diclofenac this is predicted to range from 0.1-8.3% of river lengths exceeding 100 ng/L (2.4% 247 
expected exceedance) in the three scenarios (Fig. 2, Fig. S1 and S2).  248 
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 249 
FIGURE 1.  Location of European surface waters where EE2 concentrations are predicted to exceed 250 
0.035 ng/L (yellow) and 0.35 ng/L (red) based on expected chemical discharge (mean excretion 251 
and mean sewage removal)  252 
 253 
 254 
FIGURE 2. Predicted average river water concentrations throughout the European river network 255 
based on expected chemical discharge (mean excretion and mean sewage removal) and their 256 
proximity to the proposed EQS values in COM(2011)876 257 
 258 
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 259 
TABLE 3. Predicted proportion of national river length that would exceed the suggested annual 260 
average EQS based on expected chemical discharge 261 
EE2 (0.035 ng/L AA EQS) E2 (0.4 ng/L AA EQS) Diclofenac (100 ng/L AA 
EQS) 
>30% Netherlands, 
Germany, 
Macedonia, 
Romania, 
Poland, 
Slovakia, 
Belgium, 
Bosnia, Serbia 
>5% Romania*, Czech 
R., Netherlands 
>10% Germany 
25-30% Czech R., 
Hungary, 
England 
4-5% Slovakia, 
Hungary, 
Germany, Italy, 
England 
8-10% Spain, Romania, 
Netherlands 
20-25% Portugal, 
Albania, 
Denmark, 
Bulgaria, 
Greece 
3-4% Spain, Portugal, 
Poland, 
Denmark, 
Albania, 
Belgium, 
Macedonia 
5-8% Poland, Czech 
R., Hungary, 
Italy 
15-20% Italy, 
Switzerland, 
Austria,  
2-3% Bulgaria, 
Luxembourg, 
Serbia,  
3-5% Slovakia, 
Portugal, 
Belgium, Serbia, 
Macedonia, 
England 
10-15% Spain, 
Luxembourg, 
Croatia 
1-2% Greece, Austria, 
France,  
1-3% Albania, 
Bulgaria, 
Luxembourg, 
Austria, Greece, 
Denmark, 
Switzerland 
<10% France, Ireland, 
Slovenia, 
Lithuania, 
Estonia, 
Wales/Scotland, 
Finland, Latvia, 
Sweden, 
Norway 
<1% Croatia, 
Switzerland, 
Ireland, Slovenia, 
Lithuania, 
Estonia, 
Wales/Scotland, 
Finland, Latvia, 
Sweden, 
Norway, Bosnia 
<1% Croatia, Ireland, 
Slovenia, 
France, 
Lithuania, 
Estonia, 
Wales/Scotland, 
Finland, Latvia, 
Sweden, 
Norway, Bosnia 
*Values provided for 32 European nations.  The UK was separated into England and 262 
Wales/Scotland/Northern Ireland.  Cyprus and Iceland were not included due to uncertainties in the 263 
ability to simulate their chemical concentrations. 264 
 265 
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It is possible to examine the proportion of river length that would exceed the suggested EQS on a 266 
national basis in the expected scenario (Table 3).  Some countries, such as the Netherlands, Czech 267 
Republic, Romania and Germany appear to have the most exposed rivers, whilst the rivers in the 268 
Scandinavian countries and Baltic Republics are typically least exposed.  The high, or low, exposure 269 
of some countries does not always seem intuitive and it is worth reviewing the principal controlling 270 
factors captured in the model predictions: 271 
 High populations discharging into small rivers. 272 
 Above, or below average national consumption of the specific drug. 273 
 Low sewer connection (eg in Belgium only considered to be 60%) as septic tanks are 274 
assumed to not be directly connected to rivers. 275 
 Receiving waste from upstream neighbouring countries, such as the Netherlands (important 276 
where in-stream attenuation is low). 277 
 It is the nature of averages that they can be highly influenced by transient very low flows, 278 
which can occur more frequently in some countries than others (eg Spain, Romania and UK). 279 
 Where the GWAVA model does not have specific information on the sewage effluent 280 
discharge points (eg Poland, Bosnia Herzegovina, Serbia), it estimates a discharge point 281 
relative to the population centre and the nearest water course.  This could lead to too high 282 
modelled concentrations as discharge may be incorrectly ascribed to small tributaries. 283 
 The range of predicted concentrations can be rather narrow in some country’s rivers.  The 284 
choice of the EQS value can then dramatically change the percentage of river length 285 
exceeding that EQS. 286 
The national exposure to these chemicals can only be considered a preliminary guide, but 287 
nevertheless it will hopefully stimulate further study and debate. 288 
Implications.  Given the enormous difficulties in measuring picogram concentrations of E2 289 
and EE2 in rivers, currently our best hope in assessing exposures throughout Europe is through 290 
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modelling. With its global scope, models like GWAVA can be applied to continents, such as Europe, 291 
to assess possible river concentrations of pollutants originating from the human population.  292 
However, with a 6 x 9 km grid cell, its precision is limited and in some countries the sewage effluent 293 
discharge locations are also only estimated.  Similarly, in this modelling exercise where the precise 294 
national consumption of a drug was not known, a European mean had to be applied.  Despite these 295 
limitations, the clear message from this modelling exercise was that using the expected scenario 296 
over 10% of continental Europe’s rivers (25% assuming a worst case scenario) would exceed a 0.035 297 
ng/L EE2 AA EQS.  For many European countries, a quarter to a third of their rivers would fail such a 298 
standard.   If a 0.035 ng/L EE2 AA EQS were to be applied across Europe, it would represent an 299 
enormous technical and financial challenge to meet, given the extent of likely failure predicted here. 300 
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